SHL Medical, a provider of advanced drug delivery systems such as autoinjectors, pen injectors, and specialty delivery systems, has announced a strategic partnership with Grand River Aseptic Manufacturing (GRAM), a contract development and manufacturing organization (CDMO) specializing in sterile injectable biologics and scalable pharmaceutical manufacturing solutions, to introduce fill-finish services for the RTU cartridge used in Maggie 5.0 autoinjectors.
 
The Maggie 5.0 mL, an extension of SHL’s cartridge-based 3.0 mL Maggie autoinjector, is designed for large-volume drug delivery. Equipped with SHL’s Needle Isolation Technology (NIT), this 2-step autoinjector features a permanently concealed needle, removing the need for patients to manually attach the needle before each use, thereby enhancing ease of use and safety.
 
GRAM brings significant experience in aseptic fill-finish to their partners. GRAM’s drive to improve patient care and increase collaboration on drug delivery devices will greatly benefit pharmaceutical clients through this partnership.
 
The partnership allows SHL Medical and GRAM to offer pharmaceutical companies an integrated solution for large volume autoinjectors combining SHL’s expertise in developing and manufacturing innovative drug delivery solutions and GRAM’s unique experience with filling large volume containers. Pharmaceutical organizations can now benefit from an established supply chain and faster market entry for the Maggie 5.0 autoinjector.
 
Markus Puusepp, SHL Medical’s Chief Growth Officer, commented: “The partnership with GRAM underlines our commitment to providing comprehensive solutions that address the growing needs of our pharmaceutical partners. By combining SHL’s innovative drug delivery systems with GRAM’s expertise in aseptic fill-finish, we are well-positioned to bring effective solutions to market more efficiently, benefiting both our partners and the patients they serve.”
 
Dave Powell, Vice President of Business Development at Grand River Aseptic Manufacturing, added: “We are thrilled to partner with SHL Medical to support the Maggie 5.0 autoinjector. This partnership supports GRAM’s vision of being recognized as a CDMO leader in both fill and finish services and drug delivery solutions. Our patient-centered culture and dedication to our partner’s success align perfectly with SHL’s dedication to innovation in drug delivery. Together, we are creating a streamlined solution that will offer significant value to pharmaceutical companies and, ultimately, patients.”